PIK3CA and breast cancer: Notable examples include the phase III SOLAR‐1 trial [24], which demonstrated improved progression‐free survival with the addition of alpelisib to fulvestrant in PIK3CA‐mutant [22] hormone receptor‐positive breast cancer patients, and the ongoing IPATunity130 [25] trial evaluating ipatasertib in combination with paclitaxel for advanced triple‐negative breast cancer.